Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Functional obstruction of the colon leading to megacolon in the absence of obvious colonic diseases or mechanical obstruction. When this condition is acquired, acute, and coexisting with another medical condition (trauma, surgery, serious injuries or illness, or medication), it is called Ogilvie's syndrome.
Biomarker and diagnostic research for colonic pseudo-obstruction has been reported in the published literature.
No approved treatments are currently available for colonic pseudo-obstruction. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for colonic pseudo-obstruction, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for colonic pseudo-obstruction. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
No clinical trials have been registered for colonic pseudo-obstruction.
96 publications have been identified in PubMed for colonic pseudo-obstruction. Research spans Case Report / Case Series (60%), Review / Meta-Analysis (22%), and Basic Science / Preclinical (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 58 | 60% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 5:30 AM UTC
Common questions about colonic pseudo-obstruction
Designated
Exclusivity End |
|---|
Designation Status |
|---|
neostigmine | neostigmine | Luitpold Pharmaceuticals, Inc. | 2013 | — | Designated |
View trials for colonic pseudo-obstruction
21 |
22% |
Laboratory research | 7 | 7% |
Disease patterns and progression | 4 | 4% |
Testing and diagnosis research | 3 | 3% |
Clinical study results | 2 | 2% |
Other research | 1 | 1% |
Zain A (2026). [PMID: 42222613](https://pubmed.ncbi.nlm.nih.gov/42222613/). *ACG Case Rep J*. [Case Report / Case Series]
Monteiro I (2026). [PMID: 41694880](https://pubmed.ncbi.nlm.nih.gov/41694880/). *Cureus*. [Case Report / Case Series]
Pham LN (2026). [PMID: 41798469](https://pubmed.ncbi.nlm.nih.gov/41798469/). *Cureus*. [Case Report / Case Series]
Ali MA (2026). [PMID: 41771681](https://pubmed.ncbi.nlm.nih.gov/41771681/). *Cleveland Clinic journal of medicine*. [Review / Meta-Analysis]
Geraghty E (2026). [PMID: 41717303](https://pubmed.ncbi.nlm.nih.gov/41717303/). *Journal of craniovertebral junction & spine*. [Case Report / Case Series]
Palmisani F (2026). [PMID: 41586926](https://pubmed.ncbi.nlm.nih.gov/41586926/). *International journal of colorectal disease*. [Review / Meta-Analysis]
Nagao S (2026). [PMID: 41681036](https://pubmed.ncbi.nlm.nih.gov/41681036/). *Neurogastroenterology and motility*. [Case Report / Case Series]
Applegarth J (2026). [PMID: 41241450](https://pubmed.ncbi.nlm.nih.gov/41241450/). *The Surgical clinics of North America*. [Review / Meta-Analysis]
Chatterjee A (2026). [PMID: 40980931](https://pubmed.ncbi.nlm.nih.gov/40980931/). *The American journal of gastroenterology*. [Basic Science / Preclinical]
DiBenedetto L (2026). [PMID: 41602512](https://pubmed.ncbi.nlm.nih.gov/41602512/). *ACG case reports journal*. [Case Report / Case Series]